Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri, 63104, United States.
Center for Clinical Pharmacology, St. Louis College of Pharmacy, Saint Louis, Missouri, 63110, United States.
Eur J Med Chem. 2023 Oct 5;258:115582. doi: 10.1016/j.ejmech.2023.115582. Epub 2023 Jun 25.
Estrogen-related receptors (ERR) are an orphan nuclear receptor sub-family that play a critical role in regulating gene transcription for several physiological processes including mitochondrial function, cellular energy utilization and homeostasis. They have also been implicated to play a role in several pathological conditions. Herein, we report the identification, synthesis, structure-activity relationships and pharmacological evaluation of a new chemical series of potent pan-ERR agonists. This template was designed for ERRγ starting from the known acyl hydrazide template and compounds such as agonist GSK-4716 employing a structure-based drug design approach. This led to the preparation of a series of 2,5-disubstituted thiophenes from which several were found to be potent agonists of ERRγ in cell-based co-transfection assays. Additionally, direct binding to ERRγ was established through H NMR protein-ligand binding experiments. Compound optimization revealed that the phenolic or aniline groups could be replaced with a boronic acid moiety, which was able to maintain activity and demonstrated improved metabolic stability in microsomal in vitro assays. Further pharmacological evaluation of these compounds showed that they had roughly equivalent agonist activity on ERR isoforms α and β representing an ERR pan-agonist profile. One potent agonist, SLU-PP-915 (10s), which contained a boronic acid moiety was profiled in gene expression assays and found to significantly upregulate the expression of ERR target genes such as peroxisome-proliferator activated receptor γ co-activators-1α, lactate dehydrogenase A, DNA damage inducible transcript 4 and pyruvate dehydrogenase kinase 4 both in vitro and in vivo.
雌激素相关受体(ERR)是孤儿核受体亚家族的一种,在调节包括线粒体功能、细胞能量利用和动态平衡在内的几种生理过程的基因转录中起着关键作用。它们也被认为在几种病理条件下发挥作用。在此,我们报告了一种新型的全 ERR 激动剂的鉴定、合成、构效关系和药理学评价的新化学系列。该模板是从已知的酰基酰肼模板和激动剂 GSK-4716 等化合物出发,针对 ERRγ 设计的,采用基于结构的药物设计方法。这导致了一系列 2,5-取代噻吩的制备,其中一些在基于细胞的共转染测定中被发现是强效 ERRγ 激动剂。此外,通过 H NMR 蛋白-配体结合实验确立了与 ERRγ 的直接结合。通过优化化合物,发现酚基或苯胺基可以被硼酸部分取代,这能够保持活性,并在微粒体体外试验中显示出改善的代谢稳定性。这些化合物的进一步药理学评价表明,它们对 ERR 同工型α和β具有大致相当的激动剂活性,代表了一种全 ERR 激动剂特征。一种强效激动剂 SLU-PP-915(10s),其中含有硼酸部分,在基因表达测定中进行了分析,发现它能显著上调 ERR 靶基因如过氧化物酶体增殖物激活受体 γ 共激活因子-1α、乳酸脱氢酶 A、DNA 损伤诱导转录物 4 和丙酮酸脱氢酶激酶 4 的表达,无论是在体外还是体内。